Novartis and Bristol Myers Pause CAR-T Trials Over Safety Concerns

Key Facts

1Novartis and Bristol Myers paused CAR-T autoimmune trials following patient deaths and severe side effects.

In a move reflecting heightened caution within the biotech sector, Novartis and Bristol Myers Squibb have suspended clinical trials for CAR-T cell therapies in autoimmune diseases. The pause was triggered by reports of significant safety concerns, including patient fatalities and severe side effects. According to reports, these developments raise alarms regarding the safety profile of CAR-T treatments when applied to non-oncology indications.

Major pharmaceutical players are facing increased scrutiny as these clinical trial challenges emerge, potentially impacting sentiment across the biotechnology industry. Per market data, NVS shares stood at $163.09 at close on September 03, 2026, having traded between a day high of $164.48 and a day low of $161.42 during that session.

Investors are now watching for further regulatory feedback and the potential long-term impact on the autoimmune drug pipeline. Based on the current calendar, there are no immediate upcoming catalysts for Novartis, leaving the market to focus on official communications regarding the safety review of these specific cell therapies.